Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Pipeline Review, H1 2016

Published: Jun, 2016 | Pages: 173 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Pipeline Review, H1 2016', provides in depth analysis on Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) targeted pipeline therapeutics. 

The report provides comprehensive information on the Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1)
- The report reviews Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) Overview 11
Therapeutics Development 12
Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Products under Development by Stage of Development 12
Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Products under Development by Therapy Area 13
Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Products under Development by Indication 14
Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Pipeline Products Glance 17
Late Stage Products 17
Early Stage Products 18
Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Products under Development by Companies 19
Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Products under Development by Universities/Institutes 30
Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Therapeutics Assessment 32
Assessment by Monotherapy/Combination Products 32
Assessment by Mechanism of Action 33
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Companies Involved in Therapeutics Development 39
Advenchen Laboratories, LLC 39
Amgen Inc. 40
ArQule, Inc. 41
Astellas Pharma Inc. 42
AstraZeneca Plc 43
Asubio Pharma Co., Ltd. 44
AVEO Pharmaceuticals, Inc. 45
Bayer AG 46
BioArctic Neuroscience AB 47
Boehringer Ingelheim GmbH 48
Bristol-Myers Squibb Company 49
CardioVascular BioTherapeutics, Inc. 50
Celon Pharma Sp. z o.o. 51
Debiopharm International SA 52
Eddingpharm 53
Eisai Co., Ltd. 54
Eli Lilly and Company 56
F. Hoffmann-La Roche Ltd. 57
Hutchison MediPharma Limited 58
Incyte Corporation 59
Johnson & Johnson 60
Les Laboratoires Servier SAS 61
Novartis AG 62
OncoMax 64
Principia Biopharma Inc. 65
Teva Pharmaceutical Industries Ltd. 66
Vichem Chemie Research Ltd. 67
Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Drug Profiles 68
Aea-25 - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
Aea-4 - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
ARQ-087 - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
ASP-5878 - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
AZD-4547 - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
BAY-1163877 - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
BMS-986036 - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
brivanib alaninate - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
CEP-11981 - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
CPL-043 - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
CVBT-141B - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
CVBT-141C - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
Debio-1347 - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
E-7090 - Drug Profile 87
Product Description 87
Mechanism Of Action 87
R&D Progress 87
EDP-317 - Drug Profile 88
Product Description 88
Mechanism Of Action 88
R&D Progress 88
erdafitinib - Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
HMPL-012 - Drug Profile 91
Product Description 91
Mechanism Of Action 91
R&D Progress 91
HMPL-453 - Drug Profile 94
Product Description 94
Mechanism Of Action 94
R&D Progress 94
INCB-54828 - Drug Profile 95
Product Description 95
Mechanism Of Action 95
R&D Progress 95
infigratinib - Drug Profile 96
Product Description 96
Mechanism Of Action 96
R&D Progress 96
lenvatinib mesylate - Drug Profile 98
Product Description 98
Mechanism Of Action 98
R&D Progress 98
lucitanib - Drug Profile 109
Product Description 109
Mechanism Of Action 109
R&D Progress 109
LY-2874455 - Drug Profile 112
Product Description 112
Mechanism Of Action 112
R&D Progress 112
Monoclonal Antibody to Antagonize FGFR1 for Cancer - Drug Profile 113
Product Description 113
Mechanism Of Action 113
R&D Progress 113
nintedanib - Drug Profile 114
Product Description 114
Mechanism Of Action 114
R&D Progress 114
OMRCA-01 - Drug Profile 124
Product Description 124
Mechanism Of Action 124
R&D Progress 124
pazopanib hydrochloride - Drug Profile 126
Product Description 126
Mechanism Of Action 126
R&D Progress 126
pazopanib hydrochloride + pembrolizumab - Drug Profile 132
Product Description 132
Mechanism Of Action 132
R&D Progress 132
PRN-1371 - Drug Profile 133
Product Description 133
Mechanism Of Action 133
R&D Progress 133
Recombinant Protein to Agonize FGFR for Type 2 Diabetes - Drug Profile 134
Product Description 134
Mechanism Of Action 134
R&D Progress 134
Recombinant Protein to Agonize Fibroblast Growth Factor Receptor 1 for Type 2 Diabetes - Drug Profile 135
Product Description 135
Mechanism Of Action 135
R&D Progress 135
Recombinant Proteins to Agonize FGFR for Metabolic Disorders - Drug Profile 136
Product Description 136
Mechanism Of Action 136
R&D Progress 136
regorafenib - Drug Profile 137
Product Description 137
Mechanism Of Action 137
R&D Progress 137
RG-7992 - Drug Profile 145
Product Description 145
Mechanism Of Action 145
R&D Progress 145
S-49076 - Drug Profile 146
Product Description 146
Mechanism Of Action 146
R&D Progress 146
SC-0806 - Drug Profile 147
Product Description 147
Mechanism Of Action 147
R&D Progress 147
Small Molecules to Antagonize Pan FGFR for Oncology - Drug Profile 148
Product Description 148
Mechanism Of Action 148
R&D Progress 148
SUN-11602 - Drug Profile 149
Product Description 149
Mechanism Of Action 149
R&D Progress 149
Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Dormant Projects 150
Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Discontinued Products 155
Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Featured News & Press Releases 159
Jun 06, 2016: Principia Biopharma Announces Presentation of Initial Clinical Data on PRN1371 at 2016 American Society of Clinical Oncology Annual Meeting 159
Jun 01, 2016: Bayer collaborates with U.S. National Surgical Adjuvant Breast and Bowel Project to Investigate Stivarga (Regorafenib) as Additional Adjuvant Therapy in Colon Cancer 159
May 24, 2016: Eisai To Present on Lenvima at 52nd Annual Meeting of the American Society of Clinical Oncology 160
May 19, 2016: Bayer to Showcase Latest Data on Regorafenib at ASCO 2016 161
May 16, 2016: U.S. FDA Approves additional indication for Eisai anti cancer agent LENVIMA in Combination with Everolimus as Treatment  for Advanced Renal Cell Carcinoma 161
May 16, 2016: New Presentations at ATS 2016 Reinforce OFEV (nintedanib) Efficacy, Safety and Tolerability Across Range of Patients with idiopathic pulmonary fibrosis 162
May 09, 2016: LUME-Meso trial enrols first patient: Boehringer Ingelheim's new pivotal study investigating nintedanib for the treatment of malignant pleural mesothelioma 163
May 04, 2016: Phase III Trial of Regorafenib in Patients with Unresectable Liver Cancer Meets Primary Endpoint of Improving Overall Survival 164
Apr 20, 2016: Eisai Announces Non-Clinical Research Findings At Aacr 107Th Annual Meeting Regarding Combination Of Anticancer Agent Lenvatinib With Everolimus 165
Apr 15, 2016: Debiopharm International announces presentation at AACR of non-clinical data relating to its targeted investigational compound Debio 1347/CH5183284, a selective FGFR 1,2,3 inhibitor 165
Apr 12, 2016: Highly Anticipated New Treatment Option Now Available for Canadians with Select Type of Thyroid Cancer 166
Mar 21, 2016: Chi-Med Initiates Sulfatinib Phase III Registration Study in Pancreatic Neuroendocrine Tumor Patients 167
Mar 09, 2016: Lenvima (lenvatinib) Now Available in Israel as Important New Treatment for People with Advanced Thyroid Cancer 168
Mar 02, 2016: Chi-Med initiates sulfatinib Phase II clinical trial in thyroid cancer 169
Feb 25, 2016: Eisai Slams the New Cancer Drug Fund that Further Delays Patient Access to New Cancer Drug 170
Appendix 172
Methodology 172
Coverage 172
Secondary Research 172
Primary Research 172
Expert Panel Validation 172
Contact Us 172
Disclaimer 173

List of Tables

Number of Products under Development for, H1 2016 12
Number of Products under Development by Therapy Area, H1 2016 13
Number of Products under Development by Indication, H1 2016 14
Comparative Analysis by Late Stage Development, H1 2016 17
Comparative Analysis by Early Stage Products, H1 2016 18
Number of Products under Development by Companies, H1 2016 19
Number of Products under Development by Companies, H1 2016 (Contd..1) 20
Products under Development by Companies, H1 2016 21
Products under Development by Companies, H1 2016 (Contd..1) 22
Products under Development by Companies, H1 2016 (Contd..2) 23
Products under Development by Companies, H1 2016 (Contd..3) 24
Products under Development by Companies, H1 2016 (Contd..4) 25
Products under Development by Companies, H1 2016 (Contd..5) 26
Products under Development by Companies, H1 2016 (Contd..6) 27
Products under Development by Companies, H1 2016 (Contd..7) 28
Products under Development by Companies, H1 2016 (Contd..8) 29
Number of Products under Investigation by Universities/Institutes, H1 2016 30
Products under Investigation by Universities/Institutes, H1 2016 31
Assessment by Monotherapy/Combination Products, H1 2016 32
Number of Products by Stage and Mechanism of Action, H1 2016 34
Number of Products by Stage and Route of Administration, H1 2016 36
Number of Products by Stage and Molecule Type, H1 2016 38
Pipeline by Advenchen Laboratories, LLC, H1 2016 39
Pipeline by Amgen Inc., H1 2016 40
Pipeline by ArQule, Inc., H1 2016 41
Pipeline by Astellas Pharma Inc., H1 2016 42
Pipeline by AstraZeneca Plc, H1 2016 43
Pipeline by Asubio Pharma Co., Ltd., H1 2016 44
Pipeline by AVEO Pharmaceuticals, Inc., H1 2016 45
Pipeline by Bayer AG, H1 2016 46
Pipeline by BioArctic Neuroscience AB, H1 2016 47
Pipeline by Boehringer Ingelheim GmbH, H1 2016 48
Pipeline by Bristol-Myers Squibb Company, H1 2016 49
Pipeline by CardioVascular BioTherapeutics, Inc., H1 2016 50
Pipeline by Celon Pharma Sp. z o.o., H1 2016 51
Pipeline by Debiopharm International SA, H1 2016 52
Pipeline by Eddingpharm, H1 2016 53
Pipeline by Eisai Co., Ltd., H1 2016 54
Pipeline by Eli Lilly and Company, H1 2016 56
Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 57
Pipeline by Hutchison MediPharma Limited, H1 2016 58
Pipeline by Incyte Corporation, H1 2016 59
Pipeline by Johnson & Johnson, H1 2016 60
Pipeline by Les Laboratoires Servier SAS, H1 2016 61
Pipeline by Novartis AG, H1 2016 62
Pipeline by OncoMax, H1 2016 64
Pipeline by Principia Biopharma Inc., H1 2016 65
Pipeline by Teva Pharmaceutical Industries Ltd., H1 2016 66
Pipeline by Vichem Chemie Research Ltd., H1 2016 67
Dormant Projects, H1 2016 150
Dormant Projects (Contd..1), H1 2016 151
Dormant Projects (Contd..2), H1 2016 152
Dormant Projects (Contd..3), H1 2016 153
Dormant Projects (Contd..4), H1 2016 154
Discontinued Products, H1 2016 155
Discontinued Products (Contd..1), H1 2016 156
Discontinued Products (Contd..2), H1 2016 157
Discontinued Products (Contd..3), H1 2016 158